Back in May, the SEC raised some red flags over Valeant’s use of “non-GAAP” financial measures. And now, new correspondence from the commission shows it’s still got issues with the drugmaker’s practices.

In a series of letters made available by the SEC Wednesday, the body said Valeant’s non-GAAP adjusted net income was too similar to cash flow and told the company to stop reporting it on a per-share basis, The Wall Street Journal notes.

Valeant responded that it plans to change its non-GAAP reporting and disclosures; its edits are slated to make their debut when the company rolls out its 2017 earnings guidance and could potentially include a new adjusted net income measure, the company said.

Whitepaper Download Reducing the Complexity and Costs of Channel Planning and Logistics How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business. Download for Free

The SEC first got in touch with the Quebec-based pharma over its non-GAAP measures in a letter last December. It took particular issue with the once-acquisitive company’s practice of stripping out pickup-related expenses and also questioned what Valeant meant by “core” operating results, when operations relied on a series of large buys.

SEC staffers are “concerned with your overall format and presentation of the non-GAAP measures and believe revisions to your future earnings releases and investor materials are appropriate,” they wrote.

The SEC gripes join a long list of Valeant problems that seems to just keep getting longer. The drugmaker’s talks with Japan's Takeda over a $10 billion sale of Valeant's Salix business reportedly broke down this week, scuttling a chance for Valeant to pay down a mountain of debt and ease ongoing default worries from investors.

And industry watchers are also still wondering whether more charges are on the way in a federal kickbacks case for the embattled drugmaker or its former C-suiters; U.S. authorities have already charged former company exec Gary Tanner and Andrew Davenport, the former CEO of Valeant-linked specialty pharmacy Philidor, with engineering a multimillion-dollar fraud and kickbacks scheme.